The agent was found to decrease the production of Tumor Necrosis Factor alpha (TNFα) and Interleukin-1β (IL-1β) in peritoneal macrophages [14] as well as the TNFα and the VEGF secretion by gastrointestinal neoplasms [15]. Here, TNF is linked to digestive system neoplasm.